New combo targets tough lung cancer: drug before and after radiation shows promise
NCT ID NCT06194448
First seen Nov 04, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps people with a specific genetic type of stage III lung cancer that cannot be removed by surgery. About 76 adults with EGFR-mutated non-small cell lung cancer will receive osimertinib first, then chemoradiation, then continue osimertinib. The goal is to see if this approach delays cancer growth and is safe, but lifelong medication is needed, so it aims to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Palo Alto, California, 94304, United States
-
Research Site
Beijing, 100021, China
-
Research Site
Changsha, 410013, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150081, China
-
Research Site
Hefei, 230001, China
-
Research Site
Jinan, 250117, China
-
Research Site
Nanning, 530021, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430071, China
-
Research Site
Zhengzhou, 450052, China
-
Research Site
Haifa, 31096, Israel
-
Research Site
Jerusalem, 91031, Israel
-
Research Site
Tel Aviv, 62748, Israel
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Suwon, 16247, South Korea
-
Research Site
Barcelona, 08003, Spain
-
Research Site
Donostia / San Sebastian, 20014, Spain
-
Research Site
Granada, 18016, Spain
-
Research Site
Madrid, 28007, Spain
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Bangkok, 10210, Thailand
-
Research Site
Bangkok, 10330, Thailand
-
Research Site
Chiang Rai, 57000, Thailand
-
Research Site
Hat Yai, 90110, Thailand
-
Research Site
Khon Kaen, 40002, Thailand
-
Research Site
Ankara, 06010, Turkey (Türkiye)
-
Research Site
Yenimahalle, 06560, Turkey (Türkiye)
-
Research Site
Hanoi, 100000, Vietnam
-
Research Site
Ho Chi Minh City, 700000, Vietnam
Conditions
Explore the condition pages connected to this study.